Hepatitis C Virus. Current and Evolving Treatments for Genotypes 2 and 3

Gastroenterology Clinics of North America

Volumn 44, Issue 4, 2015, Pages 845-857

  Ampuero, Javier ^a   Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Direct acting antiviral; Genotype 2; Genotype 3; Hepatitis C; Sustained virologic response

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; INTERFERON; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PLACEBO; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VELPATASVIR;

CHRONIC KIDNEY FAILURE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MONOTHERAPY; NONHUMAN; REVIEW; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; TREATMENT OUTCOME;

EID: 84947613087     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.07.009     Document Type: Review

References (41)

1. Marcellin P., Cheinquer H., Curescu M., et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012, 56:2039-2050.
2. Zeuzem S., Hultcrantz R., Bourliere M., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004, 40:993-999.
3. Bourlière M., Barberin J.M., Rotily M., et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 2002, 9:62-70.
4. Bourlière M., Benali S., Ansaldi C., et al. Optimal therapy of genotype-2 chronic hepatitis C: what's new?. Liver Int 2015, 35(Suppl 1):21-26.
5. Herbst D.A., Reddy K.R. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013, 22:527-536.
6. Lawitz E., Lalezari J.P., Hassanein T., et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial. Lancet Infect Dis 2013, 13:401-408.
7. Herbst D.A., Reddy K.R. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013, 22:1337-1346.
8. Dore G.J., Lawitz E., Hézode C., et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 2015, 148:355-366.
9. Moreno C., Berg T., Tanwandee T., et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012, 56:1247-1253.
10. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
11. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368:1867-1877.
12. Zeuzem S., Dusheiko G.M., Salupere R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014, 370:1993-2001.
13. Sulkowski M.S., Naggie S., Lalezari J., et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014, 312:353-361.
14. Omata M., Nishiguchi S., Ueno Y., et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014, 21:762-768.
15. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221.
16. Lawitz E., Sullivan G., Rodriguez-Torres M., et al. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect 2015, 70:197-205.
17. Gower E., Estes C.C., Hindman S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014, 61:45-57.
18. Ampuero J., Romero-Gómez M., Reddy K.R. HCV genotype 3 - the new treatment challenge. Aliment Pharmacol Ther 2014, 39:686-698.
19. Rubbia-Brandt L., Quadri R., Abid K., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000, 33:106-115.
20. Ampuero J., Del Campo J.A., Rojas L., et al. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. Ann Hepatol 2014, 13:356-363.
21. Bochud P.Y., Cai T., Overbeck K., et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009, 51:655-666.
22. Leandro G., Mangia A., Hui J., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006, 130:1636-1642.
23. Nkontchou G., Ziol M., Aout M., et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011, 18:516-522.
24. Ampuero J., Del Campo J.A., Rojas L., et al. Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. Genes Immun 2015, 16:297-300.
25. Foster G., Pianko S., Cooper C., et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study. J Hepatol 2015, S1:1-186.
26. Nelson D.R., Cooper J.N., Lalezari J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015, 61:1127-1135.
27. Gane E.J., Hyland R.H., An D., et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in HCV infected populations including decompensated patients and patients with prior sofosbuvir treatment experience. Gastroenterology 2014, 146:S904-S905.
28. Gane E.J., Hyland R., An D., et al. Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the Electron2 study. Hepatology 2014, 60:1045-1695.
29. Gane E.J., Hyland R.H., An D., et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology 2014, 60:1042-1695.
30. Pianko S., Flamm S., Shiffman M., et al. High efficacy of treatment with sofosbuvir + GS-5816 ± ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV infection. Hepatology 2014, 60:1045-1695.
31. Najafzadeh M., Andersson K., Shrank W.H., et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015, 162:407-419.
32. Linas B.P., Barter D.M., Morgan J.R., et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 Infection. Ann Intern Med 2015, 162(9):619-629.
33. Eslam M., Leung R., Romero-Gomez M., et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol 2014, 61:235-241.
34. Romero-Gómez M., Viloria M.M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
35. Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol 2015, 12(5):284-292.
36. Romero-Gómez M., Turnes J., Ampuero J., et al. Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study. PLoS One 2015, 10:e0122613.
37. Quer J., Gregori J., Rodríguez-Frias F., et al. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. J Clin Microbiol 2015, 53:219-226.
38. Harvoni (ledipasvir/sofosbuvir) prescribing information 2014, Gilead Sciences, Foster City (CA).
39. Romero-Gómez M., Berenguer M., Molina E., et al. Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. J Hepatol 2013, 59:1323-1330.
40. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015, 63(1):199-236.
41. Abraham G.M., Spooner L.M. Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks. Clin Infect Dis 2014, 59:411-415.